DrugPatentWatch Database Preview

Patent: 9,694,088

« Back to Dashboard

Summary for Patent: 9,694,088

Title:	Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Abstract:	Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.
Inventor(s):	Govindan; Serengulam V. (Summit, NJ), McBride; William J. (Boonton, NJ), Sathyanarayan; Nalini (Edison, NJ), Mazza-Ferreira; Christine (Park Ridge, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	15/270,542
Patent Claims:	see list of patent claims

Details for Patent 9,694,088

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	1978-01-10		2033-02-07
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	2011-03-25		2033-02-07
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	2015-01-23		2033-02-07
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	2014-12-22		2033-02-07
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	2017-10-04		2033-02-07